Skip to main content
SpringerLink
Log in

Infliximab in rheumatology

  • Chapter
TNF-alpha Inhibitors

Part of the book series: Milestones in Drug Therapy ((MDT))

  • 977 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chu CQ, Field M, Feldmann M, Maini RN (1991) Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34(9): 1125–1132

    PubMed  CAS  Google Scholar 

  2. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397–440

    Article  PubMed  CAS  Google Scholar 

  3. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89(20): 9784–9788

    Article  PubMed  CAS  Google Scholar 

  4. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA (1992) Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89(16): 7375–7379

    Article  PubMed  CAS  Google Scholar 

  5. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36(12): 1681–1690

    PubMed  CAS  Google Scholar 

  6. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30(16): 1443–1453

    Article  PubMed  CAS  Google Scholar 

  7. Harriman G, Harper LK, Schaible TF (1999) Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis 58Suppl 1: I61–I64

    Article  PubMed  CAS  Google Scholar 

  8. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344(8930): 1105–1110

    Article  PubMed  CAS  Google Scholar 

  9. Paulus HE, Egger MJ, Ward JR, Williams HJ (1990) Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 33(4): 477–484

    PubMed  CAS  Google Scholar 

  10. Kavanaugh AF, Cush JJ, St Clair EW (1996) Anti-TNF-alpha monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX); results of a double-blind, placebo controlled multicenter trial. Arthritis Rheum 39(suppl): S123

    Google Scholar 

  11. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6): 727–735

    PubMed  CAS  Google Scholar 

  12. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9): 1552–1563

    Article  PubMed  CAS  Google Scholar 

  13. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194): 1932–1939

    Article  PubMed  CAS  Google Scholar 

  14. Lipsky P, van der Heijde DM, St Clair EW, Smolen J, Furst D, Kablen J (2000) 102-week clinical and radiologic results from the ATTRACT trial: a 2 year randomized, controlled, phase 3 trial of infliximab (Remicade) in patients with active RA despite methotrexate. Arthritis Rheum 43 (Abstract): S269

    Google Scholar 

  15. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22): 1594–1602

    Article  PubMed  CAS  Google Scholar 

  16. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH et al (2004) Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50(4): 1051–1065

    Article  PubMed  CAS  Google Scholar 

  17. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB (1989) Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1(8646): 1036–1038

    PubMed  Google Scholar 

  18. van der Heijde DM (1996) Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 10(3): 435–453

    Article  PubMed  Google Scholar 

  19. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23(2): 137–145

    PubMed  CAS  Google Scholar 

  20. Ware JE, Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6): 473–483

    PubMed  Google Scholar 

  21. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der H D et al (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52(4): 1020–1030

    Article  PubMed  CAS  Google Scholar 

  22. Prevoo ML, ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1): 44–48

    PubMed  CAS  Google Scholar 

  23. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR et al (2004) Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63(2): 149–155

    Article  PubMed  CAS  Google Scholar 

  24. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11): 3432–3443

    Article  PubMed  CAS  Google Scholar 

  25. Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF, Van Zeben D, Kerstens PJ, Hazes JM et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 52(11): 3381–3390

    Article  PubMed  CAS  Google Scholar 

  26. Quinn MA, Conaghan PG, O’Connor PJ, Karim Z, Greenstein A, Brown A et al (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52(1): 27–35

    Article  PubMed  CAS  Google Scholar 

  27. Robinson DM, Keating GM (2005) Infliximab: in ankylosing spondylitis. Drugs 65(9): 1283–1291

    Article  PubMed  CAS  Google Scholar 

  28. Van den B F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59(6): 428–433

    Article  Google Scholar 

  29. Fredriksson T, Pettersson U (1978) Severe psoriasis — oral therapy with a new retinoid. Dermatologica 157(4): 238–244

    Article  PubMed  CAS  Google Scholar 

  30. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43(6): 1346–1352

    Article  PubMed  CAS  Google Scholar 

  31. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4): 499–505

    PubMed  CAS  Google Scholar 

  32. Braun J, Bollow M, Seyrekbasan F, Haberle HJ, Eggens U, Mertz A et al (1996) Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 23(4): 659–664

    PubMed  CAS  Google Scholar 

  33. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21(12): 2286–2291

    PubMed  CAS  Google Scholar 

  34. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21(12): 2281–2285

    PubMed  CAS  Google Scholar 

  35. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21(9): 1694–1698

    PubMed  CAS  Google Scholar 

  36. Baeten D, Kruithof E, Van den B F, Demetter P, Van Damme N, Cuvelier C et al (2001) Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 44(1): 186–195

    Article  PubMed  CAS  Google Scholar 

  37. Kruithof E, Baeten D, Van den B F, Mielants H, Veys EM, De Keyser F (2005) Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 64(4): 529–536

    Article  PubMed  CAS  Google Scholar 

  38. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313): 1187–1193

    Article  PubMed  CAS  Google Scholar 

  39. MacKay K, Mack C, Brophy S, Calin A (1998) The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 41(12): 2263–2270

    Article  PubMed  CAS  Google Scholar 

  40. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G et al (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 48(8): 2224–2233

    Article  PubMed  CAS  Google Scholar 

  41. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64(2): 229–234

    Article  PubMed  CAS  Google Scholar 

  42. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R et al (2005) Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44(5): 670–676

    Article  PubMed  CAS  Google Scholar 

  43. Van den B F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H et al (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46(3): 755–765

    Article  CAS  Google Scholar 

  44. Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G et al (2004) Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 63(12): 1664–1669

    Article  PubMed  CAS  Google Scholar 

  45. van der H D, Dijkmans B, Geusens P, Sieper J, Dewoody K, Williamson P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2): 582–591

    Article  CAS  Google Scholar 

  46. Anderson JJ, Baron G, van der H D, Felson DT, Dougados M (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44(8): 1876–1886

    Article  PubMed  CAS  Google Scholar 

  47. Veale DJ, Ritchlin C, FitzGerald O (2005) Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64Suppl 2: ii26–ii29

    Article  PubMed  Google Scholar 

  48. Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, de Rie MA, Bos JD et al (2004) Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 63(7): 769–773

    Article  PubMed  CAS  Google Scholar 

  49. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G et al (2001) Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144(3): 587–589

    Article  PubMed  CAS  Google Scholar 

  50. Salvarani C, Cantini F, Olivieri I, Macchioni P, Padula A, Niccoli L et al (2003) Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 49(4): 541–545

    Article  PubMed  CAS  Google Scholar 

  51. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U et al (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4): 1227–1236

    Article  PubMed  CAS  Google Scholar 

  52. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T et al (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum 39(12): 2013–2020

    PubMed  CAS  Google Scholar 

  53. Davis JC, Jr, (2004) Breaking the ice: Testing tumor necrosis factor alpha blockade in lupus. Arthritis Rheum 50(10): 3061–3063

    Article  PubMed  CAS  Google Scholar 

  54. Crispin JC, Martinez A, Alcocer-Varela J (2003) Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 21(3): 273–276

    Article  PubMed  Google Scholar 

  55. Ueda Y, Yang K, Foster SJ, Kondo M, Kelsoe G (2004) Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression. J Exp Med 199(1): 47–58

    Article  PubMed  CAS  Google Scholar 

  56. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Diaz E (1998) Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus 7(3): 154–158

    Article  PubMed  CAS  Google Scholar 

  57. Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50(10):3161–3169

    Article  PubMed  CAS  Google Scholar 

  58. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E et al (2004) Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome (TRIPSS). Arthritis Rheum 50(4): 1270–1276

    Article  PubMed  CAS  Google Scholar 

  59. Sfikakis PP (2002) Behcet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61Suppl 2: ii51–ii53

    PubMed  Google Scholar 

  60. Arayssi T, Hamra R, Homeidan F, Uthman I, Awwad ST, Mroue K et al (2005) The efficacy of a single dose of infliximab in the treatment of Behcet’s disease uveitis. Clin Exp Rheumatol 23(3):427

    PubMed  CAS  Google Scholar 

  61. Haugeberg G, Velken M, Johnsen V (2004) Successful treatment of genital ulcers with infliximab in Behcet’s disease. Ann Rheum Dis 63(6): 744–745

    Article  PubMed  CAS  Google Scholar 

  62. Kram MT, May LD, Goodman S, Molinas S (2003) Behcet’s ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 46(1): 118–121

    Article  PubMed  Google Scholar 

  63. Sarwar H, McGrath H, Jr, Espinoza LR (2005) Successful treatment of long-standing neuro-Behcet’s disease with infliximab. J Rheumatol 32(1): 181–183

    PubMed  Google Scholar 

  64. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: an open-label trial. Arthritis Rheum 52(8): 2478–2484

    Article  PubMed  CAS  Google Scholar 

  65. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM (2005) Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89(5): 533–536

    Article  PubMed  CAS  Google Scholar 

  66. Baughman RP, Iannuzzi M (2003) Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17(6): 425–431

    Article  PubMed  CAS  Google Scholar 

  67. Baughman RP, Lower EE (2001) Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18(1): 70–74

    PubMed  CAS  Google Scholar 

  68. Baughman RP, Bradley DA, Lower EE (2005) Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 43(1): 7–11

    PubMed  CAS  Google Scholar 

  69. Doty JD, Mazur JE, Judson MA (2005) Treatment of sarcoidosis with infliximab. Chest 127(3):1064–1071

    Article  PubMed  CAS  Google Scholar 

  70. Heffernan MP, Anadkat MJ (2005) Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol 141(7): 910–911

    Article  PubMed  Google Scholar 

  71. Mandel L, Wolinsky B, Chalom EC (2005) Treatment of refractory sarcoidal parotid gland swelling in a previously reported unresponsive case. J Am Dent Assoc 136(9): 1282–1285

    PubMed  Google Scholar 

  72. Thumfart J, Muller D, Rudolph B, Zimmering M, Querfeld U, Haffner D (2005) Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy. Am J Kidney Dis 45(2):411–414

    Article  PubMed  Google Scholar 

  73. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C et al (2002) Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41(10): 1126–1132

    Article  CAS  Google Scholar 

  74. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL et al (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford) 41(11): 1303–1307

    Article  CAS  Google Scholar 

  75. Arbach O, Gross WL, Gause A (2002) Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 206(5): 496–501

    Article  PubMed  CAS  Google Scholar 

  76. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I (2001) Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44(12): 2933–2935

    Article  PubMed  CAS  Google Scholar 

  77. Salvarani C, Cantini F, Niccoli L, Catanoso MG, Macchioni P, Pulsatelli L et al (2003) Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 30(4): 760–763

    PubMed  Google Scholar 

  78. Hoffman GS, Cid MC, Weyand CM, Stone JH, Rendt KE, Salvarani C (2005) Phase II study of the safety and efficacy of infliximab in giant cell arteritis (GCA): 22 week interim analysis. Arthritis Rheum 52 (abstract): S271

    Google Scholar 

  79. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50(7): 2296–2304

    Article  PubMed  CAS  Google Scholar 

  80. Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol (Berl) 99(5):585–588

    Article  CAS  Google Scholar 

  81. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L (1997) Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40(5):865–874

    PubMed  CAS  Google Scholar 

  82. Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 44(4): 562–563

    Article  CAS  Google Scholar 

  83. Hengstman GJ, van den Hoogen FH, van Engelen BG (2004) Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 52(1):61–63

    Article  PubMed  CAS  Google Scholar 

  84. Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E (2004) Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford) 43(4):531–532

    Article  CAS  Google Scholar 

  85. Uthman I, El Sayad J (2004) Refractory polymyositis responding to infliximab. Rheumatology (Oxford) 43(9): 1198–1199

    Article  CAS  Google Scholar 

  86. Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM (2002) Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 132(29–30): 414–422

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. David Geffen School of Medicine, UCLA Medical Center, Los Angeles, CA, 90095, USA

    Mihaela B. Taylor & Dahlia T. Lainer

Authors
  1. Mihaela B. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dahlia T. Lainer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, St. Luke’s-Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY, 10025, USA

    Jeffrey M. Weinberg  & Robin Buchholz  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Taylor, M.B., Lainer, D.T. (2006). Infliximab in rheumatology. In: Weinberg, J.M., Buchholz, R. (eds) TNF-alpha Inhibitors. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7438-1_6

Download citation

Publish with us

Policies and ethics

Search

Navigation